Get the latest news alerts: at Twitter.

Local Tech Wire

DURHAM, N.C. – Sales of the HIZ drug Fuzeon made by Durham-based and drug giant Roche plunged 37 percent in the fourth quarter from a year earlier, Trimeris (Nasdaq: TRMS) reported after the markets closed Tuesday.

Trimeris, which is seeking a buyer after a recent merger with a South Korean company fell, through, said Fuzeon sales worldwide fell to $25.5 million in the last quarter. In the same quarter of 2008, sales were $40.5 million.

In the U.S. and Canada, sells fell even more, down 44 percent to $9 million.

The U.S.-Canada sales were the lowest in two years. In the first quarter of 2008, sales in those markets were $17 million.

For the year, Fuzeon produced $112.2 million sales, a 33 percent drop from 2008’s total of $167 million.

In 2007, Fuzeon sales were nearly $267 million.

Trimeris plans to report its latest financial results in March.